En nombre del Grupo de Trabajo de Neuroendocrinología de la Sociedad Española de Endocrinología y Nutrición.
Información de la revista
Vol. 52. Núm. 1.
Páginas 9-17 (enero 2004)
Vol. 52. Núm. 1.
Páginas 9-17 (enero 2004)
Documentos de los grupos de trabajo
Acceso a texto completo
Guía clínica del manejo del prolactinoma y otros estados de hiperprolactinemia
Visitas
68796
Este artículo ha recibido
Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.E. Molitch.
Disorders of prolactin secretion.
Endocrinol Metab Clin North Am, 30 (2001), pp. 585-610
[2.]
M.E. Molitch.
Prolactinomas.
The pituitary, 2nd ed., pp. 455-495
[3.]
J. Schlechte, B. Sherman, N. Halmi, J. Van Gilde, F. Chaplor, K. Dolan, et al.
Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study.
Endocr Rev, 1 (1980), pp. 295-308
[4.]
J. Schlechte, K. Dolan, B. Sherman, F. Chapler, A. Luciano.
The natural history of untreated hyperprolactinemia: a prospective analysis.
J Clin Endocrinol Metab, 68 (1989), pp. 412-418
[5.]
D. Sisam, J.P. Sheehan, L.R. Sheehan.
The natural history of untreated microprolactinomas.
Fertil Steril, 48 (1987), pp. 67-71
[6.]
C. March, O. Kletzky, V. Davajan, J. Teal, M. Werss, M.H. Apiuzzo, et al.
Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas.
Am J Obstet Gynecol, 139 (1981), pp. 835-844
[7.]
J. De Schepper, J. Schiettecatte, B. Velkeniers, Z. Blumenfeld, M. Shteinberg, P. Devroey, et al.
Clinical and biological characterization of macroprolactinemia with and without prolactin- IgG complexes.
Eur J Endocrinol, 149 (2003), pp. 201-207
[8.]
R. Casamitjana.
Macroprolactinemia: interpretación diagnóstica.
Endocrinol Nutr, 50 (2003), pp. 313-316
[9.]
P. Amadori, C. Dilberis, A. Marcolla, M. Pinamonti, P. Menapace, F. Dal Bosco.
Macroprolactinemia: predicitability on clinical basis and detection by PEG precipitation with two different immunometric methods.
J Endocrinol Invest, 26 (2003), pp. 148-156
[10.]
P. Amadori, C. Dilberis, A. Marcolla.
All the studies on hyperprolactinemia should not forged the possible presence of macroprolactinemia.
Eur J Endocrinol, 150 (2004), pp. 93-94
[11.]
T. Lucas.
Problemas en el diagnóstico diferencial de las hiperprolactinemias.
Endocrinol Nutr, 51 (2004), pp. 241-244
[12.]
Y. Torres, J.J. Acebes, J. Soler.
Incidentaloma hipofisario: evaluación y abordaje terapéutico en la actualidad.
Endocrinol Nutr, 50 (2003), pp. 153-155
[13.]
Páramo C. Incidentalomas hipofisarios. Endocrinol Nutr. En prensa.
[14.]
M.J. Naidich, E.J. Russell.
Current approaches to imaging of the sellar region and pituitary.
Endocrinol Metab Clin North Am, 28 (1999), pp. 45-79
[15.]
A. Colao, A. Di Sarno, P. Cappabianca, C. Di Somma, R. Pivonello, G. Lombardi.
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
N Engl J Med, 349 (2003), pp. 2021-2031
[16.]
J.S. Bevan, J. Webster, C.W. Burke, M.F. Scanlon.
Dopamine agonists and pituitary tumor shrinkage.
Endocr Rev, 13 (1992), pp. 220-240
[17.]
I. Pellegrini, R. Rasolonjanahary, G. Gunz, I. Morarge, D. Dewarlly, J. Brownell, et al.
Resistance to bromocriptine in prolactinomas.
J Clin Endocrinol Metab, 69 (1989), pp. 500-509
[18.]
M. Molitch.
Pregnancy and the hyperprolactinemic women.
N Engl J Med, 23 (1985), pp. 1364-1370
[19.]
E. Robert, L. Musatti, G. Piscitelli, C.I. Ferrari.
Pregnancy outcome after treatment with ergot derivative, cabergoline.
Reprod Toxicol, 10 (1996), pp. 333-337
[20.]
E. Ricci, F. Parazzini, T. Motta, C.I. Ferrari, A. Colao, A. Clavenna, et al.
Pregnancy outcome after cabergoline treatment in early weeks of gestation.
Reprod Toxicol, 16 (2002), pp. 791-793
[21.]
M.E. Molitch.
Management of prolactinomas during pregnancy.
J Reprod Med, 44 (1999), pp. 1121-1126
[22.]
A. Liuzzi, D. Dallabonzana, G. Oppizzi, G.G. Verde, R. Cozzi, P. Chiodini, et al.
Low doses of dopamine agonists in the longterm treatment of macroprolactinomas.
N Engl J Med, 313 (1985), pp. 656-659
[23.]
R. Demura, O. Kubo, H. Demura, K. Shizume, K. Kitamura, et al.
Changes in computed tomographic findings in microprolactinomas before and after bromocriptine.
Acta Endocrinol, 110 (1985), pp. 308-312
[24.]
J.A. Schelechte.
Prolactinoma.
N Engl J Med, 349 (2003), pp. 2035-2041
[25.]
M. Losa, P. Mortini, R. Barzaghi, L. Gioia, M. Giovanelli.
Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome.
J Clin Endocrinol Metab, 87 (2002), pp. 3180-3186
[26.]
O. Serri, E. Rasio, H. Beauregard, J. Hardy, M. Somma.
Recurrence of hyperprolactinemia after selective transphenoidal adenomectomy in women with prolactinoma.
N Engl J Med, 309 (1983), pp. 280-283
[27.]
J.A. Schlechte, B.M. Sherman, F.K. Chapler, J. VanGilder.
Longterm follow-up of women with surgical treated prolactin-secreting pituitary tumors.
J Clin Endocrinol Metab, 62 (1986), pp. 1296-1301
Copyright © 2005. Sociedad Española de Endocrinología y Nutrición